Latest News

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Most readers would already be aware that OPmobility's (EPA:OPM) stock increased significantly by 13% over the past...

Key Insights Wilh. Wilhelmsen Holding's significant private companies ownership suggests that the key decisions are...

Schindler Holding AG ( VTX:SCHN ) saw a double-digit share price rise of over 10% in the past couple of months on the...

SES S.A. ( BDL:SESGL ) shares have had a really impressive month, gaining 27% after a shaky period beforehand. The...

When close to half the companies in Sweden have price-to-earnings ratios (or "P/E's") below 22x, you may consider ASSA...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...

Aurizon Holdings has completed an on-market share buy-back and cancelled over 36 million ordinary shares, while 212,819 performance rights have lapsed unvested, modestly reducing potential future equity issuance. Together, these actions tighten prospective dilution and indicate a focus on capital returns and incentive discipline, with no immediate cash-flow impact disclosed. We will now explore how Aurizon’s sizeable share cancellation could influence its investment narrative, including...

Deere (DE) is heading into its upcoming earnings release with several pressure points in focus, including more than 2,000 layoffs at U.S. factories, recent EPS underperformance versus Wall Street, and a projected US$1.2b tariff hit. See our latest analysis for Deere. At a share price of US$514.40, Deere has seen a 7 day share price return of 5.39% and a 90 day share price return of 11.24%. The 5 year total shareholder return of 79.93% points to a stronger long run record, even as recent...

Fresh coverage of PagSeguro Digital (PAGS) is drawing attention to the stock, as investors weigh its current valuation, capital return plans, and the earnings sensitivity to potential Brazilian interest rate cuts that are expected in early 2026. See our latest analysis for PagSeguro Digital. At a share price of $10.08, PagSeguro Digital has delivered a 30 day share price return of 5.44% and a 90 day share price return of 11.63%, while the 1 year total shareholder return of 56.58% contrasts...

Northern Oil and Gas recently drew investor attention with commentary highlighting its roughly 8% dividend yield, expanding production from over 11,000 wells, and negative free cash flow driven by rapid growth amid weaker energy prices. This combination of high income, a diversified non-operating asset base, and questions over dividend sustainability has sharpened the focus on how resilient the company’s cash generation really is. We’ll now examine how concerns about negative free cash flow...

Event overview and why it matters for Marcus & Millichap (MMI) IPA Capital Markets, a division of Marcus & Millichap (MMI), arranged US$93.5 million in construction financing for the office to residential conversion of 830 Third Avenue in Manhattan. The deal spotlights the firm’s role in large urban redevelopment projects. See our latest analysis for Marcus & Millichap. Against this backdrop, Marcus & Millichap’s recent office to residential financing news comes after a mixed share price...

CAVA Group (CAVA) is back in focus after a cluster of upbeat analyst opinions, fresh institutional buying, a new Chief Operations Officer, and the company’s largest menu launch yet all converged to reset expectations. See our latest analysis for CAVA Group. The latest menu launch, leadership change and fresh analyst coverage have arrived alongside a 30 day share price return of 26.7% and a year to date share price return of 19.1%. This comes even as the 1 year total shareholder return sits at...

Earlier this month, ZIM Integrated Shipping Services approved the election of Ron Hadassi and Ran Gritzerstein to its Board of Directors at the January 2, 2026 AGM, while investors were informed that the company is in advanced stages of a strategic review assessing multiple acquisition proposals. These board changes, combined with an ongoing review of potential buyers, highlight how ZIM’s governance and ownership structure could materially influence its future direction and capital...

If you are wondering whether Medline is offering fair value at its current price, this article walks you through what the numbers are saying and what that could mean for you. Medline shares recently closed at US$44.12, with returns of 8.9% over the last 7 days, 5.9% over the last 30 days, and 8.6% year to date, which has put the stock on more investors' radar. Recent company updates and sector commentary around medical suppliers have given investors more information to work with, which can...

Vitalhub Corp. recently presented at the 2nd Annual Lytham Partners Healthcare Investor Summit on January 15, 2026, outlining its healthcare technology solutions for a broad investor audience. This investor-focused appearance gives management a platform to communicate how its acquisitive, SaaS-oriented model fits evolving healthcare digitization trends and funding priorities. We will now examine how management’s messaging at this healthcare investor summit could influence Vitalhub’s existing...

Ambarella (AMBA) has drawn fresh attention after CES, where it introduced the CV7 edge AI vision chip and the Ambarella Developer Zone, moves aimed at supporting faster rollouts of edge AI applications. See our latest analysis for Ambarella. Those CES launches come after a choppy stretch for the stock, with a 1 day share price return of 6.39% contrasting with a 30 day return of 5.23% and a 1 year total shareholder return of 14.93%. This suggests that long term momentum has been weak even as...

Compañía de Minas BuenaventuraA (BVN) has drawn fresh attention after a strong past 3 months, with the share price showing a 35.20% total return and a 22.33% move over the past month. See our latest analysis for Compañía de Minas BuenaventuraA. That recent momentum sits on top of a much longer run, with a 1 year total shareholder return of 175.85% and a 3 year total shareholder return above 3x, while the current share price is US$34.68 after a small 1 day pullback. If this kind of move has...

Viridian Therapeutics recently announced that the FDA has accepted its Biologics License Application for thyroid eye disease drug veligrotug, granting Priority Review with a target decision date of June 30, 2026, while the company also progresses a European filing and pivotal phase 3 trials for elegrobart (VRDN-003). This cluster of regulatory milestones meaningfully advances Viridian’s thyroid eye disease franchise, concentrating attention on how its pipeline could reshape treatment options...

Stanmore Resources (ASX:SMR) has been in focus after reporting record quarterly run of mine coal production of 5.3 million tonnes, a 14% lift in saleable output to 3.6 million tonnes, and a final dividend that outpaced market expectations. See our latest analysis for Stanmore Resources. The recent production update and above expectation dividend have arrived alongside strong momentum, with a 30 day share price return of 26.58% and a 90 day return of 31.00%. The 1 year total shareholder return...

Disc Medicine (IRON) is back in focus after the FDA extended its review of the company’s experimental therapy bitopertin, citing questions around trial data integrity and potential abuse risk. See our latest analysis for Disc Medicine. Those FDA questions and the recent executive hire have played out against a softer tape, with the 7 day share price return of 9.23% and 90 day share price return of 18.63% contrasting with a 1 year total shareholder return of 21.78% and a very large 3 year...

Why Benchmark Electronics is in Focus After a CTO Change Benchmark Electronics (BHE) is back on investor radars after appointing Josh Hollin as Senior Vice President and Chief Technology Officer, following the planned retirement of long serving engineering leader Jan Janick. See our latest analysis for Benchmark Electronics. The CTO transition comes after a stretch of firm price momentum, with a 7 day share price return of 9.86% and a 90 day share price return of 15.71%. The 5 year total...

Shift4 Payments, Inc. recently declared a US$1.50 per-share cash dividend on its 6% Series A Mandatory Convertible Preferred Stock, and refinanced about US$997,500,000.00 of term loans at lower interest margins under an amended first-lien credit agreement. At the same time, analysts have turned more cautious on Shift4’s organic growth prospects amid softer same-store sales in core hospitality and restaurant customers, even as new verticals and geographies contribute more. With Deutsche...

In recent days, United Therapeutics has faced a mix of developments, including insider share sales by senior executives, a completed Phase 3 Ralinepag trial in pulmonary arterial hypertension, and continued analyst coverage ahead of its January 12, 2026 presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Amid these events, analysts have highlighted Ralinepag’s trial completion and the Tyvaso franchise as key drivers for United Therapeutics’ long-term pulmonary...